Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle
Open Access

Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials

Louis Bessette, Eduardo Mysler, Cassandra D. Kinch, Kenneth Kwok, Tatjana Lukic, Phu Vinh On and Ronald F. van Vollenhoven
The Journal of Rheumatology March 2022, jrheum.210707; DOI: https://doi.org/10.3899/jrheum.210707
Louis Bessette
This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Louis Bessette
Eduardo Mysler
This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cassandra D. Kinch
This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cassandra D. Kinch
Kenneth Kwok
This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kenneth Kwok
Tatjana Lukic
This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phu Vinh On
This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald F. van Vollenhoven
This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ronald F. van Vollenhoven
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Article Information

jrheum.210707
DOI 
https://doi.org/10.3899/jrheum.210707
PubMed 
35232809

Published By 
The Journal of Rheumatology
Print ISSN 
0315-162X
Online ISSN 
1499-2752
History 
  • Published online April 15, 2022.

Article Versions

  • Latest version (March 1, 2022 - 04:00).
  • Latest version (April 6, 2022 - 06:15).
  • You are currently viewing a Latest version of this article (April 15, 2022 - 04:00).
  • View the most recent version of this article
Copyright & Usage 
© 2022 The Journal of Rheumatology

Author Information

  1. Louis Bessette,
  2. Eduardo Mysler,
  3. Cassandra D. Kinch,
  4. Kenneth Kwok,
  5. Tatjana Lukic,
  6. Phu Vinh On and
  7. Ronald F. van Vollenhoven
  1. This study was sponsored by Pfizer Inc.
    L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
    LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex.
    Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com.
    Accepted for publication February 9, 2022.

Article usage

Article usage: February 2022 to April 2025

AbstractFullPdf
Feb 2022101
Mar 2022779047
Apr 202217260120
May 20222661876
Jun 20226511336155
Jul 202212896146
Aug 20225367855
Sep 20229519146
Oct 20228929328
Nov 2022647420
Dec 20221722918
Jan 20234840646
Feb 20232938319
Mar 20232341928
Apr 20233133730
May 20233235842
Jun 20233935640
Jul 20234240346
Aug 20232239236
Sep 20231933323
Oct 20234221743
Nov 20232827737
Dec 20233220428
Jan 20242730542
Feb 20242534934
Mar 20242223141
Apr 2024174653
May 2024174857
Jun 2024224658
Jul 2024145349
Aug 2024264150
Sep 2024185747
Oct 202495254
Nov 2024173738
Dec 2024327946
Jan 2025134433
Feb 2025126820
Mar 20252518799
Apr 202597866

Statistics from Altmetric.com

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 52, Issue 6
1 Jun 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials
Louis Bessette, Eduardo Mysler, Cassandra D. Kinch, Kenneth Kwok, Tatjana Lukic, Phu Vinh On, Ronald F. van Vollenhoven
The Journal of Rheumatology Mar 2022, jrheum.210707; DOI: 10.3899/jrheum.210707

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials
Louis Bessette, Eduardo Mysler, Cassandra D. Kinch, Kenneth Kwok, Tatjana Lukic, Phu Vinh On, Ronald F. van Vollenhoven
The Journal of Rheumatology Mar 2022, jrheum.210707; DOI: 10.3899/jrheum.210707
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Understanding the Psoriasis Phenotype Associated With Psoriatic Arthritis Using the PURE-4 Questionnaire: Insights From Spanish Real-World Settings
  • HLA-B27 Testing in Clinical Practice: A Retrospective Analysis of Testing Indications and Rheumatology Referral Patterns
  • Analysis of Gut-Homing Receptors in Circulating Mucosal-Associated Invariant T Cells and Their Presence in Synovial Tissue From Patients With Axial Spondyloarthritis
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire